8-K filing — Edesa Biotech, Inc. (EDSA)
Filed: 2026-11-17 AccNo: 0001171843-26-007511 Size: 189 KB Item 8.01: Other Events
Stocks · News reference
Edesa Biotech announced that the European Commission has granted orphan drug designation to its investigational drug, paridiprubart, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-17 AccNo: 0001171843-26-007511 Size: 189 KB Item 8.01: Other Events
Edesa Biotech has signed an exclusive collaboration and license agreement with KYORIN Pharmaceutical to develop and commercialize its drug candidate, paridiprubart, for Acute Respiratory Distress Syndrome (ARDS) in Japan.
Edesa Biotech, Inc. announced that its management team will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference, featuring a fireside chat and investor meetings.